Drug fends off kidney cancer progression
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease …
More: continued here
Friday, May 30th, 2008